Physician profile
Asaf Aleem
NPI 1851371405
$1,039.62
in general payments reported to CMS, 2019-2025
13 companies · $90.12 in 2025
The $90.12 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $73.58 · 2021: $175 · 2022: $126 · 2023: $279 · 2024: $17.94 · 2025: $90.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $239.28 | 2021-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $197.58 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $133.37 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $123.84 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $88.39 | 2019-2023 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $83.50 | 2019-2022 | |
| Lundbeck LLC | $66.86 | 2019-2023 | Rexulti |
| Bioxcel Therapeutics, INC. | $24.45 | 2023 | Igalmi |
| Tris Pharma INC | $22.04 | 2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $17.94 | 2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.82 | 2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $13.45 | 2021 | |
| Allergan, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asaf Aleem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.